Evidence map›Paper›PMID 26527873›Full record

ReviewInternational journal of nanomedicine2015

Diagnosis of prostate cancer via nanotechnological approach.

Benedict J Kang, Minhong Jeun, Gun Hyuk Jang, Sang Hoon Song, In Gab Jeong, Choung-Soo Kim, Peter C Searson, Kwan Hyi Lee

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of nanomedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1 (EFEMP1) Acts as a Potential Diagnostic Biomarker for Prostate Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Benedict J KangKIST Biomedical Research Institute, Korea University of Science and Technology (UST), Seoul, Republic of Korea ; Department of Biomedical Engineering, Korea University of Science and Technology (UST), Seoul, Republic of Korea.
Minhong JeunKIST Biomedical Research Institute, Korea University of Science and Technology (UST), Seoul, Republic of Korea ; Department of Biomedical Engineering, Korea University of Science and Technology (UST), Seoul, Republic of Korea.
Gun Hyuk JangKIST Biomedical Research Institute, Korea University of Science and Technology (UST), Seoul, Republic of Korea ; Department of Biomedical Engineering, Korea University of Science and Technology (UST), Seoul, Republic of Korea.
Sang Hoon SongDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
In Gab JeongDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Choung-Soo KimDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Peter C SearsonInstitute for Nanobiotechnology, Johns Hopkins University, Baltimore, MD, USA.
Kwan Hyi LeeKIST Biomedical Research Institute, Korea University of Science and Technology (UST), Seoul, Republic of Korea ; Department of Biomedical Engineering, Korea University of Science and Technology (UST), Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is one of the leading causes of cancer-related deaths among the Caucasian adult males in Europe and the USA. Currently available diagnostic strategies for patients with prostate cancer are invasive and unpleasant and have poor accuracy. Many patients have been overly or underly treated resulting in a controversy regarding the reliability of current conventional diagnostic approaches. This review discusses the state-of-the-art research in the development of novel noninvasive prostate cancer diagnostics using nanotechnology coupled with suggested diagnostic strategies for their clinical implication.

Indexed as

Biological AssayBody FluidsHumansMaleNanomedicineProstate-Specific AntigenProstatic NeoplasmsProstate-Specific Antigenbioassaybodily fluidnanodevicenanomaterialnon-PSA biomarkerPSA

Identifiers

PMID26527873
PMCPMC4621223

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.